ImmunoGen, Inc (NASDAQ: IMGN) saw its shares fall over 12% during regular trading hours on Thursday. There was no specific news that caused the drop, however, it is worth noting that the company recently announced a public offering of common stock, however, it is unclear whether or not this has had an effect. ImmunoGen has a pipeline of products that it is developing using its proprietary technology platform to create novel antibody-drug conjugates (ADCs) for the treatment of cancer. The company’s main product, mirvetuximab soravtansine, is currently in late-stage trials for the treatment of ovarian cancer. The ADC has shown promise as an effective treatment, however, the company has experienced setbacks with the clinical program, most recently pushing back the primary completion date for trials to 2022. ImmunoGen also saw positive results from the Phase 1 trial of its IMGN632 candidate, which it is developing for the treatment of acute myeloid leukemia. The candidate induced responses in 6 of 25 patients who were evaluated. Despite the share drop on Thursday, the company’s future prospects remain promising if it can deliver on its pipeline.